Efficacy of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma.

Abstract

e17045 Background: The purpose of this study was to analyze the efficacy and safety of recombinant human endostatin (endostar) combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC). Methods: 54 patients with locally advanced NPC who received endostar combined with chemoradiotherapy following neoadjuvant chemotherapy were selected as the study group, and another 46 ones with locally advanced NPC who received chemoradiotherapy following neoadjuvant chemotherapy alone were chosen as the control group at the same term. Specific chemotherapy regimen: docetaxel 75 mg/m2, DDP 80 mg/m2, every 21 days for one cycle; two cycles of neoadjuvant chemotherapy; concurrent chemotherapy with single DDP. The patients in the study group received 2 cycles of endostar (7.5 mg/m2, d8-d21 during neoadjuvant chemotherapy and d1-d14 during concurrent chemotherapy). The planned doses of IMRT to gross tumor volume and positive cervical lymph nodes were 69.96-73.92 Gy and 69.96 Gy in 33 fractions, respectively. Results: The median follow-ups were 12.5 months in the study group and 13.0 months in the control group. The efficacy of study group was slightly higher than that of control group. There were no significant differences regarding the CR of nasopharyngeal primary tumor (57.4% vs. 50.0%, p=0.321) and the CR of positive cervical lymph nodes (63.0% vs. 50.0%, p=0.052). There were no significant differences about 1-year progression-free survival (PFS) rate (94% vs. 100%, p=0.34). Compared with control group, the study group had higher incidence at grade 3+4 granulocyte reduction (42.6% vs. 21.7%, p=0.028). Three patients suffered from temporary cardiac arrhythmias events in the study group. All patients completed the study and there were no treatment-related deaths. Conclusions: The efficacy of endostar combined with chemoradiotherapy and chemotherapy for locally advanced NPC is more significant, with tolerable side effects.